4//SEC Filing
Rangwala Reshma 4
Accession 0000950170-25-034732
CIK 0001503802other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:26 PM ET
Size
5.3 KB
Accession
0000950170-25-034732
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Sale
Common Stock
2025-03-04$6.29/sh−3,587$22,562→ 29,272 total
Footnotes (2)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001825322
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:26 PM ET
- Size
- 5.3 KB